EU market entry is a commercial decision with regulatory constraints. Not the other way around.
A structured approach that starts with commercial viability. Regulatory strategy follows. For pharmaceutical manufacturers ready to enter Europe with clarity, not guesswork.
Request an assessmentPropylon is a pharmaceutical consulting firm specializing in EU market entry.
We work with non-European pharmaceutical and supplement manufacturers to assess whether EU market entry makes commercial sense, and if it does, to build the regulatory and operational path to get there. Most consultancies start with regulation. We start with commercial viability.
The EU remains one of the most commercially attractive pharmaceutical markets globally
Products registered in Europe command higher pricing in the Middle East, Latin America, and parts of Asia. EU entry is a strategic lever, not just a market.
We reverse the typical EU entry sequence. Most companies start with regulatory. We start with commercial viability.
Market sizing, pricing, distribution, and competitive landscape assessed before any regulatory commitment.
Regulatory route and manufacturing compliance aligned to the commercial strategy.
Dossier readiness, partner selection, timelines, costs, and a clear go/no-go decision.
If you are considering EU market entry, we can provide an initial assessment within one week.
No commitment required. We start with a focused conversation about your product, your timeline, and your commercial objectives. If EU entry makes sense, we outline the path. If it does not, we tell you directly.
Get in touch